Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. announced its financial results for Q1 2026 along with significant progress in its oral peptide drug development programs. The company submitted a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for osteoporosis, to the FDA and completed a bridging study for its single-tablet formulation. It expanded its collaboratio…